EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Seroconversion after immunization by a plasma-derived vaccine against hepatitis B virus: study of a 3-injection (0, 1, 6 months) protocol in Brazzaville (Congo)



Seroconversion after immunization by a plasma-derived vaccine against hepatitis B virus: study of a 3-injection (0, 1, 6 months) protocol in Brazzaville (Congo)



Bulletin de la Societe de Pathologie Exotique et de ses Filiales 83(2): 155-158



The authors report a small study of the immunogenicity of HEVAC B (Pasteur) given to 116 healthy adults (5 micro g at 0, 1 and 6 months). Seroconversion at 3, 6 and 7 months was 79%, 78%, and 87% respectively. Geometric mean titre of anti-HBs at 7 months was 773 mIU/ml.(The overall seroconversion rate is similar to that expected with a 0, 1, 2, 12-month schedule.)R.J.C.

(PDF 0-2 workdays service: $29.90)

Accession: 002219251

Download citation: RISBibTeXText



Related references

Seroconversion following immunization with a plasma-derived vaccine against hepatitis B: study of a 3-injection protocol (0, 1, 6 months) in Brazzaville (Congo). Bulletin de la Societe de Pathologie Exotique 83(2): 155-158, 1990

Active immunization against hepatitis b virus hbv with low doses of plasma derived vaccine pdv by intradermal id route. Gastroenterology 96(5 PART 2): A581, 1989

Active immunization against hepatitis B virus (HBV) with low-doses of plasma-derived vaccine by intradermal route. Revista do Instituto de Medicina Tropical de Sao Paulo 31(2): 91-94, 1989

Detection of hepatitis B virus infection markers in dried plasma spots among patients in Congo-Brazzaville. Diagnostic Microbiology and Infectious Disease 78(3): 229-231, 2014

Active immunization against hepatitis b virus hbv with low doses of plasma derived vaccine by intradermal route anti hbs response after three years of follow up. Revista do Instituto de Medicina Tropical de Sao Paulo 33(2): 167, 1991

Active immunization against hepatitis B virus (HBV) with low-doses of plasma-derived vaccine by intradermal route. Anti HBs response after 3 years of follow-up. Revista do Instituto de Medicina Tropical de Sao Paulo 33(2): 167-167, 1991

Efficacy of seroconversion and duration of immunity induced by the meningococcal serogroup C vaccine. Study included in the evaluation of the mass immunization of the population in the age group between 18 months and 19 years in the community of Madrid. Revista Espanola de Salud Publica 72(5): 401-406, 1999

Hepatitis b surface antigen a marker of the relationship between hepatitis b virus and primary cancer of the liver the situation in brazzaville congo in 1984. Williams, A O Et Al (Ed ) Iarc (International Agency For Research on Cancer) Scientific Publications, No 63 Oau (Organization Of African Unity)/Strc (Scientific Technical And Research Commission) Scientific Publications, No 1 Virus-Associated Cancers in Africa; Symposium, Nairobi, Kenya Xxxi+774p +oxford University Press: New York, N Y , Usa; International Agency For Research on Cancer: Lyon, France Illus 221-226, 1986

Erythema nodosum and Takayasu's arteritis after immunization with plasma derived hepatitis B vaccine. Journal of Rheumatology 20(8): 1417-1418, 1993

Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transplant Infectious Disease 16(5): 797-801, 2015

Efficacy and immune memory of plasma-derived hepatitis B vaccine 11 years after primary immunization. Zhonghua Yu Fang Yi Xue Za Zhi 34(2): 113-115, 2002

Universal immunization of infants with low doses of a low-cost, plasma-derived hepatitis B vaccine in South Africa. Bulletin of the World Health Organization 80(4): 277-281, 2002

Evaluation of the effectiveness nine years after primary immunization with local produced plasma-derived hepatitis B vaccine. Zhonghua Yu Fang Yi Xue Za Zhi 32(4): 205-207, 1999

Immunogenicity of plasma-derived hepatitis B vaccine: relationship to site of injection and obesity. Journal of General Internal Medicine 1(3): 199-201, 1986

The efficacy of plasma-derived hepatitis B vaccine in the sixth year after initial injection. Xi'an Yike Daxue Xuebao 16(4): 368-371, 1995